The weekly administration of docetaxel (Taxotere; Rhône-Poulenc Rorer, Antony, France) at doses up to and including 40 mg/m2 induces low levels of hematologic and nonhematologic toxicity. In particular, weekly scheduling appears to markedly reduce the incidence of neutropenia compared with regimens in which an equivalent dose rate (mg/m2/wk) is given once every 3 weeks. Encouraging responses have been reported in patients with a range of tumor types, including breast cancer, treated with weekly docetaxel. Further trials of weekly docetaxel are in progress, and it appears that this schedule may prove particularly valuable in certain elderly patients who are unsuited to more aggressive chemotherapy.